Edwards Lifesciences Reports Fourth Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Goldman Sachs to acquire real estate company LCN for up to $410M
- Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
Edwards Lifesciences (EW) PT Raised to $174 at Canaccord Genuity
February 2, 2018 7:08 AM ESTCanaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $174.00 (from $140.00) while maintaining a Buy rating. An analysis suggests the stock should trade to at least $174 by year-end, based solely on the fundamentals currently evident in the business, let alone... More
Edwards Lifesciences (EW) Tops Q4 EPS by 3c; Raises Outlook
February 1, 2018 4:17 PM ESTEdwards Lifesciences (NYSE: EW) reported Q4 EPS of $0.94, $0.03 better than the analyst estimate of $0.91. Revenue for the quarter came in at $888.5 million versus the consensus estimate of $867.09 million.
GUIDANCE:
Edwards Lifesciences sees Q1 2018 EPS of $1.04-$1.14. Edwards Lifesciences sees Q1 2018... More
